FDAnews
www.fdanews.com/articles/176078-lilly-unveils-results-on-unsuccessful-cetp-inhibitor

Lilly Unveils Results on Unsuccessful CETP Inhibitor

April 8, 2016

Six months after discontinuing a Phase 3 trial of its cholesterol candidate evacetrapib, Eli Lilly released new data showing the CETP lowered LDL cholesterol and raised HDL cholesterol, but didn’t reduce cardiovascular events.

The trial showed evacetrapib reduced unhealthy LDL cholesterol by 37 percent and increased healthy HDL cholesterol by 130 percent. But the candidate did not decrease rates of heart attacks, strokes, angina or cardiovascular deaths. Evacetrapib is the third drug in its class to fail this primary endpoint.

Preliminary data of the randomized, multi-center ACCELERATE trial, which enrolled more than 12,000 patients, indicated evacetrapib would not meet its primary endpoints. The data monitoring committee advised Eli Lilly to stop the study in October 2015.